Richard Whitt
Donation protected
My brother and his wife Katy have been dealing with so much lately, we just want to do what we can to help them.
Richard and Katy are now currently in Houston for at least 45 days. With that 45 days it comes with going through their savings and trying to find funds to help pay for the Apartment and additional expenses that they are incurring.
Everyone has been asking questions about what type of treatment, how is he, what's going on, how can we help?
Can you imagine that if everyone on their Facebook Friends list could help with even $5.00 a person, we'd be able to help them with their out of pocket expense.
Insurance is helping a little bit there is a cap and they’ve hit it. This is their 4th trip to Houston and there are over 2 more years of appointments that they will have to go back and forth to Houston for.
Richard has Diffused Large B-Cell Lymphoma,
Chemo has no affect on the tumor which is why the doctors have moved towards Car T Cell Therapy.
Here is the information for the Clinical Trial that Richard has been accepted into.
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
CAR-T Therapy (ZUMA-19)
CAR-T therapy can cost as much as $1.4 million for a one-time treatment. That estimate does not include hospital stays and other related expenses
https://lymphoma.org/wp-content/uploads/2019/10/Immunotherapy_Budde.pdf
This is the Study that Richard has been approved for:
https://clinicaltrials.gov/ct2/show/NCT04314843
Study Design
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2037
Resource links provided by the National Library of Medicine
MedlinePlus related topics: Lymphoma
Drug Information available for: Axicabtagene ciloleucel
Genetic and Rare Diseases Information Center resources: B-cell Lymphoma Lymphosarcoma
U.S. FDA Resources
#evictralph #cancersucks #lymphomawillnotwin #whittwillwin
Richard and Katy are now currently in Houston for at least 45 days. With that 45 days it comes with going through their savings and trying to find funds to help pay for the Apartment and additional expenses that they are incurring.
Everyone has been asking questions about what type of treatment, how is he, what's going on, how can we help?
Can you imagine that if everyone on their Facebook Friends list could help with even $5.00 a person, we'd be able to help them with their out of pocket expense.
Insurance is helping a little bit there is a cap and they’ve hit it. This is their 4th trip to Houston and there are over 2 more years of appointments that they will have to go back and forth to Houston for.
Richard has Diffused Large B-Cell Lymphoma,
Chemo has no affect on the tumor which is why the doctors have moved towards Car T Cell Therapy.
Here is the information for the Clinical Trial that Richard has been accepted into.
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
CAR-T Therapy (ZUMA-19)
CAR-T therapy can cost as much as $1.4 million for a one-time treatment. That estimate does not include hospital stays and other related expenses
https://lymphoma.org/wp-content/uploads/2019/10/Immunotherapy_Budde.pdf
This is the Study that Richard has been approved for:
https://clinicaltrials.gov/ct2/show/NCT04314843
Study Design
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2037
Resource links provided by the National Library of Medicine
MedlinePlus related topics: Lymphoma
Drug Information available for: Axicabtagene ciloleucel
Genetic and Rare Diseases Information Center resources: B-cell Lymphoma Lymphosarcoma
U.S. FDA Resources
#evictralph #cancersucks #lymphomawillnotwin #whittwillwin
Organizer and beneficiary
Katherine Whitt-Knox
Organizer
Marble Falls, TX
Katy Whitt
Beneficiary